These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35639932)

  • 1. Effects of BA.1/BA.2 subvariant, vaccination and prior infection on infectiousness of SARS-CoV-2 omicron infections.
    Qassim SH; Chemaitelly H; Ayoub HH; AlMukdad S; Tang P; Hasan MR; Yassine HM; Al-Khatib HA; Smatti MK; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Al-Khal A; Coyle P; Kaleeckal AH; Shaik RM; Latif AN; Al-Kuwari E; Jeremijenko A; Butt AA; Bertollini R; Al-Romaihi HE; Al-Thani MH; Abu-Raddad LJ
    J Travel Med; 2022 Sep; 29(6):. PubMed ID: 35639932
    [No Abstract]   [Full Text] [Related]  

  • 2. Estimated Effectiveness of Prior SARS-CoV-2 BA.1 or BA.2 Infection and Booster Vaccination Against Omicron BA.5 Subvariant Infection.
    Jang EJ; Choe YJ; Kim RK; Lee S; Park SK; Park YJ
    JAMA Netw Open; 2023 Mar; 6(3):e232578. PubMed ID: 36897593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines.
    He X; Su J; Ma Y; Zhang W; Tang S
    Front Immunol; 2022; 13():945930. PubMed ID: 36090988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs.
    Bekliz M; Adea K; Vetter P; Eberhardt CS; Hosszu-Fellous K; Vu DL; Puhach O; Essaidi-Laziosi M; Waldvogel-Abramowski S; Stephan C; L'Huillier AG; Siegrist CA; Didierlaurent AM; Kaiser L; Meyer B; Eckerle I
    Nat Commun; 2022 Jul; 13(1):3840. PubMed ID: 35787633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections.
    Andeweg SP; de Gier B; Eggink D; van den Ende C; van Maarseveen N; Ali L; Vlaemynck B; Schepers R; Hahné SJM; Reusken CBEM; de Melker HE; van den Hof S; Knol MJ
    Nat Commun; 2022 Aug; 13(1):4738. PubMed ID: 35961956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination.
    Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S
    Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protection.
    Torres I; Giménez E; Albert E; Zulaica J; Álvarez-Rodríguez B; Burgos JS; Peiró S; Limón R; Vanaclocha H; Rodado C; Botija P; Sifre A; Tur B; Lozano RA; Orosa I; Vicente-Ruiz M; Carrión RJ; Clari MÁ; Sánchez-Payá J; Díez-Domingo J; Comas I; González-Candelas F; Geller R; Navarro D;
    J Med Virol; 2022 Sep; 94(9):4216-4223. PubMed ID: 35585782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of SARS-CoV-2 Alpha, Beta, and Delta variants, age, vaccination, and prior infection on infectiousness of SARS-CoV-2 infections.
    Qassim SH; Hasan MR; Tang P; Chemaitelly H; Ayoub HH; Yassine HM; Al-Khatib HA; Smatti MK; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Al-Khal A; Coyle P; Gillani I; Kaleeckal AH; Shaik RM; Latif AN; Al-Kuwari E; Jeremijenko A; Butt AA; Bertollini R; Al-Romaihi HE; Al-Thani MH; Abu-Raddad LJ
    Front Immunol; 2022; 13():984784. PubMed ID: 36177014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination.
    Pedersen RM; Bang LL; Madsen LW; Sydenham TV; Johansen IS; Jensen TG; Justesen US; Andersen TE
    Emerg Infect Dis; 2022 Jun; 28(6):1274-1275. PubMed ID: 35356875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modelling the impact of the Omicron BA.5 subvariant in New Zealand.
    Lustig A; Vattiato G; Maclaren O; Watson LM; Datta S; Plank MJ
    J R Soc Interface; 2023 Feb; 20(199):20220698. PubMed ID: 36722072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases.
    Stalman EW; Wieske L; van Dam KPJ; Kummer LY; van Kempen ZLE; Killestein J; Volkers AG; Tas SW; Boekel L; Wolbink GJ; Van der Kooi AJ; Raaphorst J; Löwenberg M; Takkenberg RB; D'Haens GRAM; Spuls PI; Bekkenk MW; Musters AH; Post NF; Bosma AL; Hilhorst ML; Vegting Y; Bemelman FJ; Voskuyl AE; Broens B; Parra Sanchez A; van Els CACM; Wit J; Rutgers A; de Leeuw K; Horváth B; Verschuuren JJGM; Ruiter AM; van Ouwerkerk L; van der Woude D; Allaart CF; Teng OYK; van Paassen P; Busch MH; Jallah PBP; Brusse E; van Doorn PA; Baars AE; Hijnen DJ; Schreurs CRG; Van der Pol WL; Goedee HS; Steenhuis M; Keijzer S; Keijser JBD; Boogaard A; Cristianawati O; Ten Brinke A; Verstegen NJM; Zwinderman KAH; Rispens T; van Ham SM; Kuijpers TW; Eftimov F;
    Ann Rheum Dis; 2022 Dec; 81(12):1757-1766. PubMed ID: 36357161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. University-Associated SARS-CoV-2 Omicron BA.2 Infections, Maricopa County, Arizona, USA, 2022.
    Fowle N; Garrett B; Floyd OL; Collins J; Krasnow AD; Islas M; Holland SC; Smith MF; Lim ES; Jarrett NM; Scott SE
    Emerg Infect Dis; 2022 Jul; 28(7):1520-1522. PubMed ID: 35654405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics of liver injury in SARS-CoV-2 Omicron variant- and Omicron subvariant-infected patients.
    Deng H; Mai Y; Liu H; Guan J
    Ann Hepatol; 2023; 28(1):100763. PubMed ID: 36182032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
    Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
    Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy.
    Sormani MP; Schiavetti I; Inglese M; Carmisciano L; Laroni A; Lapucci C; Visconti V; Serrati C; Gandoglia I; Tassinari T; Perego G; Brichetto G; Gazzola P; Mannironi A; Stromillo ML; Cordioli C; Landi D; Clerico M; Signoriello E; Cocco E; Frau J; Ferrò MT; Di Sapio A; Pasquali L; Ulivelli M; Marinelli F; Pizzorno M; Callari G; Iodice R; Liberatore G; Caleri F; Repice AM; Cordera S; Battaglia MA; Salvetti M; Franciotta D; Uccelli A;
    EBioMedicine; 2022 Jun; 80():104042. PubMed ID: 35526306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations.
    Trombetta CM; Piccini G; Pierleoni G; Leonardi M; Dapporto F; Marchi S; Andreano E; Paciello I; Benincasa L; Lovreglio P; Buonvino N; Decaro N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Rappuoli R; Molesti E; Manenti A; Montomoli E
    Commun Biol; 2022 Sep; 5(1):903. PubMed ID: 36056181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levels of SARS-CoV-2 antibodies among fully vaccinated individuals with Delta or Omicron variant breakthrough infections.
    Stærke NB; Reekie J; Nielsen H; Benfield T; Wiese L; Knudsen LS; Iversen MB; Iversen K; Fogh K; Bodilsen J; Juhl MR; Lindvig SO; Øvrehus A; Madsen LW; Klastrup V; Andersen SD; Juhl AK; Andreasen SR; Ostrowski SR; Erikstrup C; Fischer TK; Tolstrup M; Østergaard L; Johansen IS; Lundgren J; Søgaard OS
    Nat Commun; 2022 Aug; 13(1):4466. PubMed ID: 35915081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection.
    Khan K; Karim F; Ganga Y; Bernstein M; Jule Z; Reedoy K; Cele S; Lustig G; Amoako D; Wolter N; Samsunder N; Sivro A; San JE; Giandhari J; Tegally H; Pillay S; Naidoo Y; Mazibuko M; Miya Y; Ngcobo N; Manickchund N; Magula N; Karim QA; von Gottberg A; Abdool Karim SS; Hanekom W; Gosnell BI; ; Lessells RJ; de Oliveira T; Moosa MS; Sigal A
    Nat Commun; 2022 Aug; 13(1):4686. PubMed ID: 35948557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superspreading of SARS-CoV-2 Omicron BA.2.23 among vaccinated Finnish adults: symptomatic COVID-19 only contracted by those without recent infection.
    Riekkinen M; Kajova M; Eriksson M; Luukkainen A; Holmberg V; Aro T; Pakkanen SH; Miettinen S; Montonen R; Smura T; Lääveri T; Kantele A
    Epidemiol Infect; 2023 Jul; 151():e113. PubMed ID: 37401478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
    Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
    J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.